Kip Ludwig started his career working for a medical device startup, developing a tool to treat hypertension and heart failure.
Now, more than a decade later, the University of Wisconsin-Madison associate professor of biomedical engineering will use that same device to improve its treatment method.
The project is being funded through a $2.5 million, four-year grant from the National Institutes of Health. Ludwig is principal investigator for the project, while UW-Madison and Wisconsin Institute for Translational Neuroengineering colleagues Justin Williams (biomedical engineering) and Aaron Suminski (neurological surgery) are co-investigators.
The device, the Barostim Neo from the company CVRx, is an implanted electrode that electrically stimulates the baroreceptors of a patient’s carotid arteries, a treatment known as baroreflex activation therapy (BAT). It received Food and Drug Administration approval in 2019.